Tumor-draining lymph node-derived lymphocyte (LNL)
Sponsors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions
Breast Neoplasms
Phase 1
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
RecruitingNCT05981001
Start: 2023-08-01End: 2035-04-30Target: 170Updated: 2023-08-08
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
RecruitingNCT05981014
Start: 2023-08-01End: 2035-05-31Target: 196Updated: 2023-08-08
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
RecruitingNCT06121570
Start: 2023-11-01End: 2031-08-31Target: 24Updated: 2023-11-08
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
RecruitingNCT06121557
Start: 2023-11-01End: 2031-12-31Target: 24Updated: 2023-11-08